27.09.2012 • News • Aveva • chemical industry • chemical industry China

Aveva, Sedin Form Strategic Alliance

Aveva today announced that it has signed a Memorandum of Understanding (MOU) in Beijing with Sedin Engineering which defines a new strategic alliance between the two companies.

The MOU will position Sedin as an Aveva technology pioneer in the China chemical industry. Sedin will gain early visibility and access to new Aveva software technology, in exchange for its valuable feedback towards current and future product development plans.

Working together on a number of new business opportunities and projects, Aveva and Sedin will develop a chemical-specific engineering software solution platform, ensuring applications are compliant with local regulatory requirements while adopting global industry best practice.

 

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.